Why MannKind Stock Tumbled on Thursday
(NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest earnings release to be lacking -- despite a significant top-line beat. MannKind closed the day down more than 7% in value.
MannKind released its fourth-quarter and full-year 2025 results before market open, reporting that revenue grew 46% year over year to just under $112 million. However, that period's tally includes almost $22.9 million from sales of edema treatment Furoscix. This became part of the company's portfolio following the October 2025 acquisition of the drug's developer, scPharmaceuticals.
Image source: Getty Images.
Source Fool.com
MannKind Corp. Aktie
1,96 €
-2,92 %
Die Aktie ist derzeit ein absoluter Favorit unserer Community mit 25 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung.
Die Community prognostiziert für MannKind Corp. ein Kursziel von 7 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 1.96 € bedeutet.
